AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New Research: Key Drivers of Growth for The Chemours, Superior Industries International, Caleres, G1 THERAPEUTICS, Vitamin Shoppe, and Ocular Therapeutix — Factors of Influence, Major Initiatives and Sustained Production

April 8, 2019

NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Chemours Company (NYSE:CC), Superior Industries International, Inc. (NYSE:SUP), Caleres, Inc. (NYSE:CAL), G1 THERAPEUTICS (NASDAQ:GTHX), Vitamin Shoppe, Inc (NYSE:VSI), and Ocular Therapeutix, Inc. (NASDAQ:OCUL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CC DOWNLOAD: http://Fundamental-Markets.com/register/?so=CC SUP DOWNLOAD: http://Fundamental-Markets.com/register/?so=SUP CAL DOWNLOAD: http://Fundamental-Markets.com/register/?so=CAL GTHX DOWNLOAD: http://Fundamental-Markets.com/register/?so=GTHX VSI DOWNLOAD: http://Fundamental-Markets.com/register/?so=VSI OCUL DOWNLOAD: http://Fundamental-Markets.com/register/?so=OCUL

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine The Chemours Company (NYSE:CC), Superior Industries International, Inc. (NYSE:SUP), Caleres, Inc. (NYSE:CAL), G1 THERAPEUTICS (NASDAQ:GTHX), Vitamin Shoppe, Inc (NYSE:VSI), and Ocular Therapeutix, Inc. (NASDAQ:OCUL) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

THE CHEMOURS COMPANY (CC) REPORT OVERVIEW

The Chemours’ Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, The Chemours reported revenue of $1,464.00MM vs $1,574.00MM (down 6.99%) and analysts estimated basic earnings per share $0.85 vs $1.23 (down 30.89%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, The Chemours reported revenue of $6,638.00MM vs $6,183.00MM (up 7.36%) and analysts estimated basic earnings per share $5.62 vs $4.04 (up 39.11%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.41. The estimated EPS forecast for the next fiscal year is $5.50 and is expected to report on February 13th, 2020.

To read the full The Chemours Company (CC) report, download it here: http://Fundamental-Markets.com/register/?so=CC

-----------------------------------------

SUPERIOR INDUSTRIES INTERNATIONAL, INC. (SUP) REPORT OVERVIEW

Superior Industries International’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Superior Industries International reported revenue of $378.82MM vs $361.80MM (up 4.70%) and analysts estimated basic earnings per share $0.50 vs -$0.50. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Superior Industries International reported revenue of $1,501.83MM vs $1,108.06MM (up 35.54%) and analysts estimated basic earnings per share $0.29 vs -$1.01. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.15. The estimated EPS forecast for the next fiscal year is -$0.02 and is expected to report on March 5th, 2020.

To read the full Superior Industries International, Inc. (SUP) report, download it here: http://Fundamental-Markets.com/register/?so=SUP

-----------------------------------------

CALERES, INC. (CAL) REPORT OVERVIEW

Caleres’ Recent Financial Performance

For the three months ended January 31st, 2019 vs January 31st, 2018, Caleres reported revenue of $720.26MM vs $702.47MM (up 2.53%) and analysts estimated basic earnings per share -$1.83 vs $0.47. For the twelve months ended January 31st, 2019 vs January 31st, 2018, Caleres reported revenue of $2,834.85MM vs $2,785.58MM (up 1.77%) and analysts estimated basic earnings per share -$0.13 vs $2.03. Analysts expect earnings to be released on May 30th, 2019. The report will be for the fiscal period ending April 30th, 2019. Reported EPS for the same quarter last year was $0.43. The estimated EPS forecast for the next fiscal year is $2.75 and is expected to report on March 19th, 2020.

To read the full Caleres, Inc. (CAL) report, download it here: http://Fundamental-Markets.com/register/?so=CAL

-----------------------------------------

G1 THERAPEUTICS (GTHX) REPORT OVERVIEW

G1 THERAPEUTICS’s Recent Financial Performance

Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.70. The estimated EPS forecast for the next fiscal year is -$3.46 and is expected to report on February 27th, 2020.

To read the full G1 THERAPEUTICS (GTHX) report, download it here: http://Fundamental-Markets.com/register/?so=GTHX

-----------------------------------------

VITAMIN SHOPPE, INC (VSI) REPORT OVERVIEW

Vitamin Shoppe’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Vitamin Shoppe reported revenue of $248.46MM vs $261.90MM (down 5.13%) and analysts estimated basic earnings per share -$0.22 vs -$0.80. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Vitamin Shoppe reported revenue of $1,114.16MM vs $1,146.50MM (down 2.82%) and analysts estimated basic earnings per share -$0.16 vs -$10.90. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.10. The estimated EPS forecast for the next fiscal year is $0.65 and is expected to report on February 25th, 2020.

To read the full Vitamin Shoppe, Inc (VSI) report, download it here: http://Fundamental-Markets.com/register/?so=VSI

-----------------------------------------

OCULAR THERAPEUTIX, INC. (OCUL) REPORT OVERVIEW

Ocular Therapeutix’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Ocular Therapeutix reported revenue of $0.50MM vs $0.49MM (up 3.49%) and analysts estimated basic earnings per share -$0.42 vs -$0.44. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Ocular Therapeutix reported revenue of $1.99MM vs $1.92MM (up 3.48%) and analysts estimated basic earnings per share -$1.57 vs -$2.20. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.40. The estimated EPS forecast for the next fiscal year is -$0.92 and is expected to report on March 5th, 2020.

To read the full Ocular Therapeutix, Inc. (OCUL) report, download it here: http://Fundamental-Markets.com/register/?so=OCUL

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Arden Dalio, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com

© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.